MEDI-528, now recognized as enokizumumab, represents a innovative medication targeting the IGF-1R , a crucial protein implicated in several dermatological diseases . Early clinical results suggest considerable potential for the management of significant itchy skin, particularly in those who have failed previous remedies. This monoclonal antibody de